Floatz logo

Conatumumab

Malignant Pancreatic Neoplasm

NantCell, Inc.monoclonal_antibodyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

330 Active assets in the Malignant Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Conatumumab is also rated in:

Locally AdvancedDormant
B
Indicative ·
63 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →
metastatic malignant neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →